ARA 290 (Cibinetide) is a novel peptide designed to selectively activate the innate repair receptor (IRR), which is a heterocomplex of the EPO receptor and the β-common (CD131) receptor.

Unlike its parent molecule, erythropoietin (EPO), ARA 290 does not bind to the classic EPO receptor that triggers erythropoiesis (red blood cell formation). Instead, it targets the IRR, which is upregulated in response to tissue injury and inflammation. By activating this pathway, ARA 290 is being investigated for its ability to:

• Attenuate inflammation

• Protect cells from apoptosis (programmed cell death)

• Promote tissue and nerve repair

This selective action makes it a significant compound in research for conditions such as diabetic neuropathy, chronic neuropathic pain, and other inflammatory or ischemic injuries, as it avoids the cardiovascular risks associated with increasing hematocrit.

Chemical & Physical Properties:

• Product: ARA 290 (Cibinetide)

• Quantity: 10 mg

• Appearance: White Lyophilized Powder

• Molecular Formula: C₅₁H₈₄N₁₆O₂₁

• Molecular Weight: 1257.3 g/mol

• Amino Acid Sequence: {Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser ({Glp} = Pyroglutamic acid)

• Purity: Typically ≥98% (via HPLC)

• Storage: Store lyophilized powder at -20°C. Once reconstituted, store in a refrigerator at 2-8°C.

• CAS Number: 1208243-50-8

For Research Use Only. This product is not intended for diagnostic, therapeutic, or human use.